About cordyceps sunshine biotech holdings co ltd - RAJAF
Cordyceps Sunshine Biotech Holdings Co., Ltd. specializes in the cultivating and sale of cordyceps. It engages in the research, development, manufacturing, and marketing of cordyceps, through its wholly-owned subsidiary, Chengdu Skyherb Biotechnology Co., Ltd. The company was founded on May 4, 2020 and is headquartered in Taipei, Taiwan.
RAJAF At a Glance
Cordyceps Sunshine Biotech Holdings Co., Ltd.
6th Floor, No. 15, Lane 548
Taipei, Taipei City 114 93
| Phone | 886-2-27489091 | Revenue | 1.25M | |
| Industry | Biotechnology | Net Income | -226,258.00 | |
| Sector | Health Technology | 2024 Sales Growth | 42.033% | |
| Fiscal Year-end | 12 / 2025 | Employees | 13 | |
| View SEC Filings |
RAJAF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 731.354 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 2,938.27 |
| Enterprise Value to EBITDA | 3,820.427 |
| Enterprise Value to Sales | 731.94 |
| Total Debt to Enterprise Value | 0.001 |
RAJAF Efficiency
| Revenue/Employee | 96,421.846 |
| Income Per Employee | -17,404.462 |
| Receivables Turnover | 4.833 |
| Total Asset Turnover | 0.312 |
RAJAF Liquidity
| Current Ratio | 0.121 |
| Quick Ratio | 0.121 |
| Cash Ratio | 0.007 |
RAJAF Profitability
| Gross Margin | 8.752 |
| Operating Margin | -14.672 |
| Pretax Margin | -15.262 |
| Net Margin | -18.05 |
| Return on Assets | -5.624 |
| Return on Equity | N/A |
| Return on Total Capital | -56.946 |
| Return on Invested Capital | N/A |
RAJAF Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 194.519 |
| Total Debt to Total Assets | 16.715 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 3.172 |